Addressing manufacturing controls for the cell and gene therapies, the subject matter experts from the industry will exchange practical experience and expectations on

• critical elements of establishing a robust CMC strategy
• CQAs (Critical Quality Attributes)
• CPPs (Critical Process Parameters)
• key factors in easing the complexity of vector production

for CGTP (cell and gene therapy products) in order to ensure the manufacturing process met technical, regulatory, and cost-efficiency standards for producing safe products. The brochure contains the additional info and the key insights.